Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma

Jean Yves Blay, Paolo Casali, Antonio Nieto, Adnan Tanović, Axel Le Cesne

Research output: Contribution to journalArticle

Abstract

Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.

Original languageEnglish
Pages (from-to)59-68
Number of pages10
JournalFuture Oncology
Volume10
Issue number1
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

trabectedin
Liposarcoma
Leiomyosarcoma
Safety
Drug Therapy
Therapeutics
Ifosfamide
Anthracyclines
Treatment Failure
Disease-Free Survival

Keywords

  • leiomyosarcoma
  • liposarcoma
  • sarcoma
  • second-line treatment
  • STS
  • trabectedin

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. / Blay, Jean Yves; Casali, Paolo; Nieto, Antonio; Tanović, Adnan; Cesne, Axel Le.

In: Future Oncology, Vol. 10, No. 1, 01.01.2014, p. 59-68.

Research output: Contribution to journalArticle

Blay, Jean Yves ; Casali, Paolo ; Nieto, Antonio ; Tanović, Adnan ; Cesne, Axel Le. / Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma. In: Future Oncology. 2014 ; Vol. 10, No. 1. pp. 59-68.
@article{12c1e31729264813a03d46941c20f5d7,
title = "Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma",
abstract = "Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9{\%}) and disease control rate (34.0 vs 26.8{\%}) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.",
keywords = "leiomyosarcoma, liposarcoma, sarcoma, second-line treatment, STS, trabectedin",
author = "Blay, {Jean Yves} and Paolo Casali and Antonio Nieto and Adnan Tanović and Cesne, {Axel Le}",
year = "2014",
month = "1",
day = "1",
doi = "10.2217/fon.13.163",
language = "English",
volume = "10",
pages = "59--68",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "1",

}

TY - JOUR

T1 - Efficacy and safety of trabectedin as an early treatment for advanced or metastatic liposarcoma and leiomyosarcoma

AU - Blay, Jean Yves

AU - Casali, Paolo

AU - Nieto, Antonio

AU - Tanović, Adnan

AU - Cesne, Axel Le

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.

AB - Aims: We aimed to evaluate the effect of prior chemotherapies on the outcomes of patients with liposarcoma and leiomyosarcoma treated with trabectedin as a 24-h infusion every 3 weeks. Patients & methods: Data from 129 patients who received trabectedin as second-line treatment following failure with an anthracycline/ifosfamide and those who had received at least two lines of prior chemotherapy were analyzed. Results: Forty seven patients received one prior regimen (group A) and 82 patients received at least two lines of chemotherapy (group B). A favorable trend in median time to progression (4.4 vs 3.0 months), progression-free survival (4.4 vs 2.6 months) and overall survival (17.4 vs 13.3 months) was found in group A. A trend toward higher overall response rate (6.4 vs 4.9%) and disease control rate (34.0 vs 26.8%) also favored group A. Both groups had equivalent safety profiles. Conclusion: All efficacy outcomes were better in patients who received trabectedin as second-line treatment compared with patients with more extensive prior therapy.

KW - leiomyosarcoma

KW - liposarcoma

KW - sarcoma

KW - second-line treatment

KW - STS

KW - trabectedin

UR - http://www.scopus.com/inward/record.url?scp=84904812022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904812022&partnerID=8YFLogxK

U2 - 10.2217/fon.13.163

DO - 10.2217/fon.13.163

M3 - Article

C2 - 23987833

AN - SCOPUS:84904812022

VL - 10

SP - 59

EP - 68

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 1

ER -